

AMENDMENTS TO THE CLAIMS

1. (previously presented): A method for preventing or treating male erectile dysfunction, which method comprises administering to a male mammal for whom such prevention or treatment is needed or desirable, an effective amount of
basic fibroblast growth factor (bFGF) protein,
thereby preventing or treating said male erectile dysfunction in said mammal.

2-3. (canceled)

4. (previously presented): The method of claim 1, wherein the mammal is a human and the bFGF protein is of human origin.

5. (previously presented): The method of claim 1, wherein the bFGF protein is administered by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, or topical administration.

6-8. (canceled)

9. (previously presented): The method of claim 1, wherein the bFGF protein is administered via a liposome.

10. (canceled)

11. (previously presented): The method of claim 1, for preventing or treating male erectile dysfunction wherein the male erectile dysfunction is erectile dysfunction induced by or secondary to nerve dysfunction, arterial insufficiency, venous leakage, hormonal insufficiency, drug use, surgery, chemotherapy or radiation.

12. (previously presented): The method of claim 1, wherein the bFGF protein is administered by intracavernous injection.

13. (previously presented): The method of claim 1, wherein the dysfunction is induced by hypercholesterolemia or induced by a cavernous nerve injury.

14-20. (canceled)

21. (previously presented): The method of claim 1, wherein the bFGF protein is administered at about 10-200 mcg/70 Kg body weight about once every two to six months.

22. (canceled)

23. (previously presented): The method of claim 1, which further comprises administering an effective amount of vascular endothelial growth factor (VEGF) protein.

24. (previously presented): The method of claim 23, wherein the VEGF protein is administered at about 10-200 mcg/70 Kg body weight about once every two to six months.

25. (previously presented): The method of claim 1, which further comprises administering an effective amount of brain derived neurotrophic factor (BDNF) protein.

26. (previously presented): The method of claim 1, wherein the BDNF protein is administered at about 10-200 mcg/70 Kg body weight about once every two to six months.

27. (previously presented): The method of claim 23, which further comprises administering an effective amount of brain derived neurotrophic factor (BDNF) protein.

28. (previously presented): The method of claim 27, wherein the BDNF protein is administered at about 10-200 mcg/70 Kg body weight about once every two to six months.

29-36. (canceled)

37. (previously presented): The method of claim 1, wherein the bFGF is in the form of a pharmaceutical composition.

38. (previously presented): The method of claim 37, wherein the composition further comprises a pharmaceutically acceptable carrier or excipient.

39. (canceled)